Actavis is one of the world's leading players in the development, manufacture, and sale of first-class generic pharmaceuticals. The successful integration of a number of acquisitions has helped position Actavis among the world’s largest companies in the industry. Founded in 1956, the Group has more than 10,000 employees operating in over 40 countries around the globe.

An extensive network of sales and marketing offices enables effective market penetration, positioning the Group strongly in the world’s largest markets for generic pharmaceuticals.

The Actavis Group is one of the world’s leading players in the development, manufacture and sale of high-quality generic pharmaceuticals.

The successful integration of a number of acquisitions has helped position Actavis among the world’s largest companies in the industry. Founded in 1956, the Group has more than 10,000 employees operating in about 40 countries around the globe. 

The Company has modern development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids and semi-solids.

Product portfolio

Actavis offers one of the broadest product portfolios and strongest pipelines in the generics industry:
 

• Around 830 products on the market
• Over 330 products under development and pending registration
• Products registered in more than 60 countries
• Over 720 product and market launches in Group markets in 2009

Future opportunities

An extensive network of sales and marketing offices enables effective market penetration, positioning the Group strongly in the world’s largest markets for generic pharmaceuticals. Strategic acquisitions, the opening of new sales offices and intensive investment in the development of generic pharmaceuticals are fuelling the growth of Actavis and have positioned the Group to take advantage of future opportunities.

The Group remains committed to leading the consolidation of a still fragmented industry through strategic acquisitions and to driving further organic growth through innovative product launches, penetration of new markets and regulatory approvals of new generic pharmaceuticals.